 Carcinoma, Pancreatic Ductal
"Carcinoma, Pancreatic Ductal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
| Descriptor ID |
D021441
|
| MeSH Number(s) |
C04.557.470.200.025.232.750 C04.557.470.615.132.750 C04.588.274.761.750 C04.588.322.475.750 C06.301.761.750 C06.689.667.625 C19.344.421.750
|
| Concept/Terms |
Carcinoma, Pancreatic Ductal- Carcinoma, Pancreatic Ductal
- Carcinomas, Pancreatic Ductal
- Ductal Carcinoma, Pancreatic
- Ductal Carcinomas, Pancreatic
- Pancreatic Ductal Carcinomas
- Duct-Cell Carcinoma of the Pancreas
- Duct Cell Carcinoma of the Pancreas
- Pancreatic Ductal Carcinoma
- Ductal Carcinoma of the Pancreas
- Pancreatic Duct Cell Carcinoma
- Carcinoma, Ductal, Pancreatic
- Duct-Cell Carcinoma, Pancreas
- Carcinoma, Pancreas Duct-Cell
- Carcinomas, Pancreas Duct-Cell
- Duct Cell Carcinoma, Pancreas
- Duct-Cell Carcinomas, Pancreas
- Pancreas Duct-Cell Carcinoma
- Pancreas Duct-Cell Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Pancreatic Ductal".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Glandular and Epithelial [C04.557.470]
- Carcinoma [C04.557.470.200]
- Adenocarcinoma [C04.557.470.200.025]
- Carcinoma, Ductal [C04.557.470.200.025.232]
- Carcinoma, Pancreatic Ductal [C04.557.470.200.025.232.750]
- Neoplasms, Ductal, Lobular, and Medullary [C04.557.470.615]
- Carcinoma, Ductal [C04.557.470.615.132]
- Carcinoma, Pancreatic Ductal [C04.557.470.615.132.750]
- Neoplasms by Site [C04.588]
- Digestive System Neoplasms [C04.588.274]
- Pancreatic Neoplasms [C04.588.274.761]
- Carcinoma, Pancreatic Ductal [C04.588.274.761.750]
- Endocrine Gland Neoplasms [C04.588.322]
- Pancreatic Neoplasms [C04.588.322.475]
- Carcinoma, Pancreatic Ductal [C04.588.322.475.750]
- Digestive System Diseases [C06]
- Digestive System Neoplasms [C06.301]
- Pancreatic Neoplasms [C06.301.761]
- Carcinoma, Pancreatic Ductal [C06.301.761.750]
- Pancreatic Diseases [C06.689]
- Pancreatic Neoplasms [C06.689.667]
- Carcinoma, Pancreatic Ductal [C06.689.667.625]
- Endocrine System Diseases [C19]
- Endocrine Gland Neoplasms [C19.344]
- Pancreatic Neoplasms [C19.344.421]
- Carcinoma, Pancreatic Ductal [C19.344.421.750]
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Pancreatic Ductal".
This graph shows the total number of publications written about "Carcinoma, Pancreatic Ductal" by people in this website by year, and whether "Carcinoma, Pancreatic Ductal" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 2 | 0 | 2 | | 2007 | 2 | 0 | 2 | | 2008 | 7 | 0 | 7 | | 2009 | 4 | 1 | 5 | | 2010 | 4 | 2 | 6 | | 2011 | 10 | 2 | 12 | | 2012 | 4 | 1 | 5 | | 2013 | 8 | 2 | 10 | | 2014 | 4 | 0 | 4 | | 2015 | 7 | 1 | 8 | | 2016 | 8 | 1 | 9 | | 2017 | 7 | 2 | 9 | | 2018 | 6 | 0 | 6 | | 2019 | 11 | 1 | 12 | | 2020 | 7 | 1 | 8 | | 2021 | 8 | 0 | 8 | | 2022 | 13 | 0 | 13 | | 2023 | 14 | 0 | 14 | | 2024 | 15 | 4 | 19 | | 2025 | 8 | 1 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Pancreatic Ductal" by people in Profiles.
-
Barrett A, Maslanka MD, Darula Z, McCabe MC, Saviola AJ, Schmitt LR, Weaver V, Pitts TM, Messersmith WA, Hansen KC. Pancreatic Cancer Progression Involves Increased Lysyl Oxidase-Mediated Collagen Cross-Links as Part of the Desmoplastic Reaction. Biochemistry. 2025 Aug 19; 64(16):3515-3525.
-
Hasselgren K, Williamsson C, Wennerblom J, Ghorbani P, Liljefors MG, Huhta H, Heby M, Månsson C, Johansson MI, Elander NO, Nortunen M, Kallio R, Halimi A, Öhlund D, Sandström P, Sparrelid E, Björnsson B. Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocol. BMC Surg. 2025 Jul 19; 25(1):299.
-
Bonsdorff A, Kjeseth T, Sahakyan M, Kirkegård J, de Ponthaud C, Ghorbani P, Wennerblom J, Williamson C, Acher AW, Thillai M, Tarvainen T, Uutela A, Sirén J, Kokkola A, Hagen RE, Lund A, Nielsen MF, Fristedt R, Biörserud C, Bratlie SO, Tingstedt B, Labori KJ, Gaujoux S, Wigmore SJ, Hallet J, Sparrelid E, Kleive D, Sallinen V. Impact of neoadjuvant therapy on short-term outcomes after left pancreatectomy: A propensity score-matched international multicenter study. Surgery. 2025 Sep; 185:109552.
-
Cotton K, Comer C, Caporali S, Butera A, Gurres S, Capradossi F, D'Alessandro A, Amelio I, Niklison-Chirou MV. Lipidome atlas of p53 mutant variants in pancreatic cancer. Biol Direct. 2025 Apr 11; 20(1):51.
-
Panja S, Kapoor E, Siddhanta K, Jogdeo CM, Sil D, Khan RI, Kumari N, Ding L, Gendelman HE, Singh AB, Oupický D. Bioactive polymers as stimulus-responsive anti-metastatic combination agents to treat pancreatic cancer. Biomaterials. 2025 Sep; 320:123255.
-
Rompen IF, Stoop TF, van Roessel S, van Veldhuisen E, Janssen QP, Alseidi A, Balduzzi A, Balzano G, Berrevoet F, Bonds M, Busch OR, Butturini G, Javed AA, Del Chiaro M, Conlon KC, Falconi M, Frigerio I, Fusai GK, Gagnière J, Griffin O, Hackert T, Sparrelid E, Halimi A, Labori KJ, Malleo G, Marino MV, Mortensen MB, Nikov A, Lesurtel M, Keck T, Kleeff J, Pandé R, Pfeiffer P, Pietrasz D, Roberts KJ, Sa Cunha A, Salvia R, Strobel O, Tarvainen T, van Laarhoven HWM, Groot Koerkamp B, Loos M, Michalski CW, Besselink MG, Hank T. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Ann Surg. 2025 May 01; 281(5):852-860.
-
Rangelova EB, Ghorbani P, Valente R, Tanaka K, Halimi A, Arnelo U, Segersvärd R, Sparrelid E, Del Chiaro M. Overcoming the technical challenge of venous resection with pancreatectomy: Which factors determine survival? Eur J Surg Oncol. 2025 Aug; 51(8):109629.
-
Gadwa J, Yu J, Piper M, Knitz MW, Darragh LB, Olimpo N, Corbo S, Beynor JI, Neupert B, Nguyen AT, Hodgson C, Nguyen D, Abdelazeem KN, Saviola A, Pousse L, Bransi A, Pincha M, Klein C, Amann M, Karam SD. Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment. J Immunother Cancer. 2025 Jan 07; 13(1).
-
Andel PCM, van Goor IWJM, Augustinus S, Berrevoet F, Besselink MG, Bhojwani R, Boggi U, Bouwense SAW, Cirkel GA, van Dam JL, Djanani A, Dorcaratto D, Dreyer S, den Dulk M, Frigerio I, Ghorbani P, Goetz MR, Groot Koerkamp B, Gryspeerdt F, Hidalgo Salinas C, Intven M, Izbicki JR, Jorba Martin R, Kauffmann EF, Klug R, Liem MSL, Luyer MDP, Maglione M, Martin-Perez E, Meerdink M, de Meijer VE, Nieuwenhuijs VB, Nikov A, Nunes V, Pando E, Radenkovic D, Roeyen G, Sanchez-Bueno F, Serrablo A, Sparrelid E, Tepetes K, Thakkar RG, Tzimas GN, Verdonk RC, Ten Winkel M, Zerbi A, Groot VP, Molenaar IQ, Daamen LA, van Santvoort HC. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. JAMA Surg. 2025 Jan 01; 160(1):74-84.
-
Madani SP, Mohseni A, Mirza-Aghazadeh-Attari M, Shahbazian H, Afyouni S, Borhani A, Zandieh G, Laheru D, Kamel IR. Role of volumetric tumor enhancement on CT in predicting overall survival in patients with unresectable pancreatic ductal adenocarcinoma. Clin Imaging. 2025 Jan; 117:110365.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|